SPG21 sirna

SPG21 siRNA (Rat)

Cat. Num. AAA827183

• Reactivity: Rat
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: SPG21; SPG21 siRNA (Rat); Maspardin; Spastic paraplegia 21 autosomal recessive Mast syndrome protein homolog; SPG21 sirna

• Host: Synthetic
• Reactivity: Rat
• Specificity: SPG21 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 261

• Applicable Applications for SPG21 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat SPG21 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for SPG21 sirna

siRNA to inhibit SPG21 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 55741780
• NCBI GeneID: 300791
• NCBI Accession #: NP_001006988.1
• NCBI GenBank Nucleotide #: NM_001006987.1
• UniProt Accession #: Q5XIC4
• Molecular Weight: 29,576 Da
• NCBI Official Full Name: maspardin
• NCBI Official Synonym Full Names: spastic paraplegia 21 homolog (human)
• NCBI Official Symbol: Spg21
• NCBI Protein Information: maspardin
• UniProt Protein Name: Maspardin
• Protein Family: Maspardin
• UniProt Gene Name: Spg21
• UniProt Entry Name: SPG21_RAT

Uniprot Description

SPG21: May play a role as a negative regulatory factor in CD4- dependent T-cell activation. Defects in SPG21 are the cause of spastic paraplegia autosomal recessive type 21 (SPG21); also known as Mast syndrome. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG21 is associated with dementia and other central nervous system abnormalities. Subtle childhood abnormalities may be present, but the main features develop in early adulthood. The disease is slowly progressive, and cerebellar and extrapyramidal signs are also found in patients with advanced disease. Patients have a thin corpus callosum and white-matter abnormalities. Belongs to the AB hydrolase superfamily. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Unknown function

Cellular Component: nucleoplasm; trans-Golgi network transport vesicle; cytoplasm; nucleus; cytosol

Molecular Function: CD4 receptor binding